Form 4: Gravitas Capital LP Boosts Stake in Tharimmune, Inc. with Significant Share Purchase

Gravitas Capital LP, a 10% owner, director, and Executive Chairman of Tharimmune, Inc., has increased its beneficial ownership in the company through a direct purchase of common stock.

Summary

• Gravitas Capital LP, identified as a Director, 10% Owner, and Executive Chairman of Tharimmune, Inc. (THAR), reported a transaction on June 20, 2025.
• The transaction involved the direct acquisition of 337,838 shares of Tharimmune Common Stock.
• The shares were purchased at a price of $1.48 per share.
• Following this transaction, Gravitas Capital LP's total beneficial ownership in Tharimmune, Inc. Common Stock stands at 732,424 shares.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a key stakeholder (10% owner, director, and Executive Chairman), indicating strong confidence in the company's prospects.

Positives

• The purchase of 337,838 shares by Gravitas Capital LP, a significant insider (10% owner, director, and Executive Chairman), signals strong confidence in Tharimmune, Inc.'s future prospects and valuation.
• Insider buying at $1.48 per share suggests that a key stakeholder believes the stock is undervalued or poised for growth.

Future Outlook

The document does not contain explicit forward-looking statements or guidance from the company. However, the insider purchase itself can be interpreted as a positive forward-looking signal from a key stakeholder.

Industry Context

This insider purchase by a significant stakeholder in Tharimmune, Inc. (a biotechnology/pharmaceutical company) suggests internal confidence, which is a positive signal within the often volatile and research-intensive biotech sector. Such transactions can be particularly impactful in smaller-cap companies where insider sentiment carries more weight.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this Form 4, insider buying, especially by a 10% owner and executive, is generally viewed as a strong indicator of management's belief in the company's future performance, often outperforming general market sentiment or analyst consensus.
• In the biotech industry, where success is often tied to clinical trial outcomes and regulatory approvals, such a significant insider investment can be interpreted as a positive sign regarding upcoming milestones or the long-term value proposition, contrasting with companies experiencing insider selling or no significant insider activity.

Related Party Transactions

• The reported transaction is a related party transaction, as Gravitas Capital LP is a 10% owner, director, and Executive Chairman of Tharimmune, Inc., making its purchase of company stock an insider dealing.

Stakeholder Impact

• Shareholders: The insider purchase is likely to be perceived positively by existing and potential shareholders, potentially boosting investor confidence and the stock price.
• Management/Employees: May reinforce morale and alignment of interests between management and shareholders.

Next Steps

• Investors will likely monitor future SEC filings from Gravitas Capital LP and other insiders for further changes in beneficial ownership.
• The market will observe Tharimmune, Inc.'s stock performance to see if this insider buying correlates with positive operational or financial news.

Key Dates

Recommendation

Keywords

Tharimmune Inc., THAR, Gravitas Capital LP, Insider Trading, SEC Form 4, Stock Purchase, Beneficial Ownership, Executive Chairman, Biotechnology, Pharmaceuticals